Washington University School of Medicine, St. Louis, MO.
Department of Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, MO.
Ann Vasc Surg. 2022 Nov;87:124-139. doi: 10.1016/j.avsg.2022.05.026. Epub 2022 Jun 9.
In individuals with heritable thoracic aortic disease (HTAD), endovascular repair for treatment of aortic aneurysm and dissection may be lifesaving, but is associated with increased risk of failure of endovascular repair and adverse outcomes. This study reports our experience with early and late outcomes of endovascular aortic and branch vessel repair in patients with HTAD.
A retrospective case series was performed by chart review of individuals with HTAD followed at Washington University School of Medicine/Barnes-Jewish Hospital who underwent endovascular aortic and/or branch vessel repair. Clinical features, imaging characteristics, and short- and long-term outcomes were collected.
Twenty-nine patients with HTAD (20 male; mean age 45 ± 13 years) underwent 37 endovascular procedures between 2006 and 2020 with mean follow up of 54 ± 41 months. Seven patients underwent two or more separate endovascular procedures. Each procedure was considered separate for data collection and analysis. Underlying conditions included Marfan syndrome (n = 16 procedures), Loeys-Dietz syndrome (n = 14 procedures), vascular Ehlers-Danlos syndrome (n = 3 procedures), and nonsyndromic HTAD (n = 4 procedures). Twenty patients (69%) had prior open surgical aortic repair. Indications for endovascular aortic repair (n = 31) included urgent repairs of acute complications of aortic dissection (n = 10) or aneurysm rupture (n = 3), and elective aortic repair (n = 18; 10 chronic dissections and eight chronic aneurysms). Six patients underwent elective endovascular repair of six branch vessel aneurysms or dissections. Six patients underwent hybrid open surgical and endovascular repair. Of the 37 procedures, 25 (68%) proximal landing zones were in the native aorta or branch vessel, 11 (30%) were in a surgical graft or elephant trunk and one was in a previously placed endograft. Thirty-six (97%) procedures were technically successful, and none required emergency surgical conversion. Two patients died: one from sepsis and one from presumed late pseudoaneurysm rupture, for a 5% per-procedure mortality rate. Two procedures were complicated by stroke and one patient developed paraparesis. Of the 31 aortic procedures, seven aortic endografts (23%) developed a stent-induced new entry (SINE) discovered with imaging at 20 ± 15 days post-procedure. Seven endografts (23%) developed a Type I endoleak and eight (26%) developed a Type II endoleak. No Type III endoleaks were seen. Within 30 days, two endografts (of 37, 5%) required reintervention. After 30 days, fifteen additional endografts (of 37, 41%) required reintervention. Two patients (of 6, 33%) who underwent hybrid repair required reintervention.
This study is the largest single-center case series examining outcomes of HTAD patients following endovascular repair. Urgent and elective endovascular repairs in patients with HTAD can manage acute and chronic complications of aortic aneurysm and dissection with relatively low risk. However, risk of early and late endoleaks and SINE is high. Close post-procedural surveillance is required, and many individuals will require additional interventions. Hybrid repair shows promise and requires further investigation.
在遗传性胸主动脉疾病(HTAD)患者中,血管内修复治疗主动脉瘤和夹层可能是救命的,但与血管内修复失败和不良结果的风险增加有关。本研究报告了我们在 HTAD 患者中进行血管内主动脉和分支血管修复的早期和晚期结果的经验。
通过对华盛顿大学医学院/巴恩斯-犹太医院接受血管内主动脉和/或分支血管修复的 HTAD 患者的病历回顾,进行了回顾性病例系列研究。收集了临床特征、影像学特征以及短期和长期结果。
29 名 HTAD 患者(20 名男性;平均年龄 45±13 岁)在 2006 年至 2020 年间接受了 37 次血管内手术,平均随访 54±41 个月。7 名患者接受了两次或更多次单独的血管内手术。每个手术都被认为是单独的数据收集和分析。基础疾病包括马凡综合征(n=16 例)、Loeys-Dietz 综合征(n=14 例)、血管性埃勒斯-当洛斯综合征(n=3 例)和非综合征性 HTAD(n=4 例)。20 名患者(69%)有先前的开放手术主动脉修复。血管内主动脉修复的指征(n=31)包括急性主动脉夹层(n=10)或动脉瘤破裂(n=3)并发症的紧急修复,以及择期主动脉修复(n=18;10 例慢性夹层和 8 例慢性动脉瘤)。6 名患者接受了 6 个分支血管动脉瘤或夹层的择期血管内修复。6 名患者接受了杂交开放手术和血管内修复。在 37 例手术中,25 例(68%)近端着陆区位于原生主动脉或分支血管内,11 例(30%)位于外科移植物或象鼻内,1 例位于先前放置的血管内移植物内。36 例(97%)手术技术成功,无一例需要紧急手术转换。2 名患者死亡:1 例死于败血症,1 例死于推测的迟发性假性动脉瘤破裂,手术死亡率为 5%。2 例手术并发中风,1 例患者出现截瘫。在 31 例主动脉手术中,7 个主动脉内支架(23%)在术后 20±15 天的影像学检查中发现支架诱导的新入口(SINE)。7 个内支架(23%)出现 I 型内漏,8 个(26%)出现 II 型内漏。未发现 III 型内漏。30 天内,2 个内支架(37 个中的 5%)需要再次干预。30 天后,另外 15 个内支架(37 个中的 41%)需要再次干预。2 名(6 名中的 33%)接受杂交修复的患者需要再次干预。
本研究是最大的单中心病例系列研究,检查了 HTAD 患者血管内修复后的结果。HTAD 患者的紧急和择期血管内修复可以相对较低的风险处理主动脉瘤和夹层的急性和慢性并发症。然而,早期和晚期内漏和 SINE 的风险很高。需要密切的术后监测,许多患者将需要额外的干预。杂交修复显示出前景,需要进一步研究。